A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Exclusion Criteria

• •1. Subjects with active central nervous system (CNS) metastasis.
• •2. Subjects with a history of malignant tumors within 5 years prior to the first dose
• •3. Subjects with uncontrolled cancer pain.
• •4. Subjects with severe cardiovascular disease.
• •5. Subjects with clinically significant hemorrhage
• •6. Subjects with uncontrolled pleural effusion, peritoneal effusion and pericardial effusion
• •7. Subjects highly suspected of interstitial lung disease
• •8. Subjects with serious infection within 4 weeks prior to the first dose
• •9. Known history of human immunodeficiency virus (HIV)，active hepatitis B virus or hepatitis C virus infection.
• •10. The adverse events of previous antineoplastic therapy did not recover to NCI-CTCAE≤ grade 1
• •11. Subjects who received anti-cancer treatment within 4 weeks prior to the first dose
• •12. Subjects who received major surgery within 4 weeks prior to the first dose
• •13. Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose.
• •14. Female subjects who were pregnant, lactating, or planned to become pregnant during the study period
• •15. Known allergic to any component of investigational drugs
• •16. Alcohol abuse, drug abuse, other serious medical conditions (including mental illness) requiring combined treatment, and other conditions that may affect subject safety or data collection.
• •17. Based on the investigator's judgment, subjects with other conditions that may affect study results, interfere with study procedures,